BRAF and melanoma: In particular, selective targeting using BRAF inhibitors is effective in most (up to 80%) BRAFV600E mutant melanomas, but the promising results observed in melanoma monotherapy were not reproduced in colorectal cancer patients, with a response rate of approximately 5% [7,8].